ClinicalTrials.gg
RecruitingNCT06342167Updated Oct 7, 2026

Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma

A Phase 2 interventional study of Radiotherapy and Programmed Cell Death Protein 1 Inhibitor in Locally Advanced Esophageal Squamous Cell Carcinoma, Sintilimab and Radiotherapy, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Recruiting at 10 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.
Updated Oct 7, 2026Now RecruitingSite recruiting status changed+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
57
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 197 studies testing Immune checkpoint inhibitors in Esophageal Squamous Cell Carcinoma — 95 open to participants now, 109 under way, 17 of them phase 3. A drug class: Immune checkpoint inhibitors · Esophageal Squamous Cell Carcinoma.

Planned enrollment
89th of 197
57 · median 50
Started
2024
with 27 others
Phase 2
130 of 197
65 open now
Primary completion
2026-12
later than 52 of 108 live
Registered
139th of 197
by date

Among the 197 studies testing Immune checkpoint inhibitors in Esophageal Squamous Cell Carcinoma, this one is the 89th largest by planned enrollment, is one of 28 that started in 2024, is one of 130 in phase 2, reaches primary completion later than 52 of the 108 other live ones, and was the 139th registered.

Esophageal Squamous Cell Carcinoma

679 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 269 are open to participants now.

Browse Esophageal Squamous Cell Carcinoma studies →

Open to participants now

95 of the 197 studies testing Immune checkpoint inhibitors in Esophageal Squamous Cell Carcinoma are open now, in 12 countries. Recruiting first, the newest first:

90 more — sign in →

By country, each count listing its studies:

All 95 open studies →

About Immune checkpoint inhibitors

A class of medicines: which ones, and the studies of each, are on its page →

Who these studies take

Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 197 studies testing Immune checkpoint inhibitors in Esophageal Squamous Cell Carcinoma, or all of them as a file.
02

Study summary

At present, concurrent chemoradiotherapy (cCRT) with platin-based dual-drug regimen is the standard treatment for inoperable, locally advanced esophageal cancer in patients with a good performance status. However, cCRT has substantial toxic effects, and a large number of patients with older age, malnutrition and other morbidities, cannot tolerate cCRT. Several phase II trials showed combining PD-1 inhibitor with definitive cCRT provided encouraging activity and acceptable toxicity in patients with locally advanced esophageal squamous cell carcinoma (LA-ESCC).

Therefore, this single-arm, multicenter, phase II trial aims to assess the efficacy and safety of immunotherapy plus radiotherapy with immunonutrition support in patients with LA-ESCC and positive PD-L1 expression who are intolerant to cCRT.

Read the detailed description

This single-arm trial is designed to evaluate the efficacy and safety of concurrent immunotherapy (sintilimab) plus radiotherapy with immunonutrition support (enteral nutritional emulsion (TPF-T) followed by consolidation immunotherapy in inoperable patients with locally advanced or early stage esophageal squamous cell carcinoma , who are PD-L1 positive expression and intolerant to cCRT. The eligible patients will receive concurrent treatment consisting of total dose of 50-60 Gy in 25-30 fractions and 200 mg of sintilimab administered every three weeks, along with enteral nutritional emulsion (TPF-T) support (600-1600 ml per day according to the nutrition status evaluation). The primary outcome is 1-year progression-free survival (PFS) rate. The investigators hypothesized PD-L1 inhibitor plus radiotherapy will improve the 1-year PFS from 40% to 60%. Then, 58 patients will be needed in total. The secondary outcomes will include objective response rate (ORR), overall survival (OS), progression-free and overall survival, and incidence of adverse events.

This study is approval by the National GCP Center for Anticancer Drugs, Independent Ethics Committee, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College (Study ID: 24/074-4354).

03

Conditions studied

  • Locally Advanced Esophageal Squamous Cell Carcinoma
  • Sintilimab
  • Radiotherapy
  • Concurrent Chemoradiotherapy
  • Immunonutrition
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18 years or order.
  2. Diagnosed with locally advanced or early stage esophageal squamous cell carcinoma by pathological examinations of the primary lesion and imaging examinations, which are not resectable.
  3. Confirmed to be unresectable and unable to tolerate synchronous chemoradiotherapy by multidisciplinary consultation, and has not undergone systemic drug therapy in the past.
  4. tumor proportion score or combined positive score of ≥1%.
  5. At least one on imaging according to the (RECIST) version 1.1.
  6. An (ECOG) performance status score of 0 -2.
  7. Expected survival time of more than three months.
  8. Adequate organ function defined as the following laboratory indicators:

    1. (ANC) ≥ 1.5×109/L without use of granulocyte colony-stimulating factor in the past 14 days.
    2. count ≥ 100×109/L without blood transfusion in the past 14 days.
    3. > 9g/dL without blood transfusion or use of erythropoietin-stimulating agents in the past 14 days.
    4. Total ≤ 1.5× (ULN).
    5. (AST) and alanine aminotransferase (ALT) ≤ 2.5×ULN.
    6. Creatinine ≤ 1.5×ULN and calculated using the Cockcroft-Gault formula) ≥ 60 ml/min.
    7. Good coagulation function, defined as an (INR) or prothrombin time (PT) ≤ 1.5×ULN.
    8. Normal thyroid function, defined as thyroid-stimulating hormone (TSH) within the normal range. If the baseline TSH is outside the normal range, subjects with total T3 (or FT3) and FT4 within the normal range can still be included.
    9. Normal cardiac enzyme spectrum (or clinically insignificant laboratory abnormalities as determined by the investigator)
  9. Negative pregnancy test (urine or serum) within 3 days before the first dose of study drug for female subjects of . If the urine pregnancy test cannot be confirmed as negative, a blood pregnancy test is required. Non-childbearing potential female is defined as for at least 1 year or has undergone surgical sterilization or hysterectomy.
  10. Willing to sign the form.

Exclusion criteria

Exclusion Criteria:

Subjects with any of the following conditions cannot participate in the study:

  1. A high risk of bleeding or perforation due to clear invasion of adjacent organs (large arteries or trachea) by the tumor, or with fistula.
  2. Diagnosed with other than esophageal cancer within 3 years prior to the first dose (excluding cured basal cell carcinoma or squamous cell carcinoma of the skin and/or radically resected carcinoma in situ).
  3. Previous immunological or immunomodulatory drugs as systemic whole-body treatment, including thymic peptides, interferon, interleukins, except for local use to control pleural effusion.
  4. Previous chest radiotherapy.
  5. A history of allogeneic organ transplantation (except for corneal transplantation) or hematopoietic stem cell transplantation.
  6. Allergic to the study drug, Sintilimab, or its .
  7. A history of (HIV) infection (i.e., HIV1/2 antibody positive).
  8. Untreated active defined as HBsAg positive and HBV-DNA copy number greater than the value in the laboratory of the study center.

    Note: Patients with hepatitis B who meet the following criteria can also be included:

    1. HBV viral load \<1000 copies/ml (200IU/ml) before the first dose; the patient should receive anti-HBV treatment throughout chemotherapy in the entire study to avoid viral reactivation.
    2. For patients who are anti-HBc (+), HBsAg (-), anti-HBs (-), and HBV viral load (-), no prophylactic anti-HBV treatment is required, but close monitoring of viral reactivation is needed.
  9. Active virus (HCV) infection defined as HCV antibody positive and HCV-RNA levels higher than the detection limit.
  10. Having received within 30 days prior to the first dose (Cycle 1, Day 1).

    Note: It is allowed to receive inactivated virus vaccines for seasonal influenza within 30 days prior to the first dose, but attenuated live influenza vaccines administered intranasally are not allowed.

  11. Pregnant or lactating women;
  12. Any serious or uncontrollable systemic diseases, such as:

    1. Significant and symptomatic abnormalities in rhythm, conduction or morphology on resting , such as complete left bundle branch block, second-degree or higher heart block, ventricular arrhythmia, or atrial fibrillation;
    2. Unstable angina, congestive heart failure, or chronic heart failure classified as (NYHA) class ≥ 2;
    3. Any arterial thrombosis, embolism or ischemic events, such as myocardial infarction, unstable angina, cerebrovascular accident or , occurring within 6 months prior to enrollment;
    4. Poor blood pressure control defined as systolic blood pressure > 140 mmHg and/or diastolic blood pressure > 90 mmHg;
    5. A history of non-infectious pneumonia requiring therapy within 1 year prior to initial treatment, or current clinical activity of interstitial lung disease;
    6. Active pulmonary tuberculosis;
    7. Active or uncontrolled infections requiring systemic therapy;
    8. Active diverticulitis, abdominal abscess, or gastrointestinal obstruction;
    9. Liver diseases such as cirrhosis, decompensated liver disease, acute or chronic active hepatitis;
    10. Poorly controlled diabetes (fasting blood glucose (FBG) > 10mmol/L);
    11. Urine protein ≥ ++ on routine urinalysis, with confirmed 24-hour urine protein quantification > 1.0 g;
    12. Psychiatric disorders that are unable to comply with treatment.
  13. Any other medical histories, disease evidence, treatment, or laboratory values that may interfere with the test results, hinder the full participation in the study, or other situations that the investigator deems unsuitable for inclusion due to potential risks.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
57 participants (estimated)

Study arms

  • Experimental
    Concurrent immunotherapy and radiotherapy

    Sintilimab + radiotherapy + enteral nutritional emulsion (TPF-T)

    Radiation: Radiotherapy · Drug: Programmed Cell Death Protein 1 Inhibitor · Dietary Supplement: Immunonutrition support

Interventions

  • RadiationRadiotherapy

    Interventions consist of 50-60 Gy in 25-30 fractions of radiotherapy.

  • DrugImmune checkpoint inhibitorsStudies of Immune checkpoint inhibitorsImmune checkpoint inhibitors pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    200 mg of Sintilimab administered every three weeks concurrently with radiotherapy and after radiotherapy as consolidation therapy up to 1year.

    Also known as: PD-1 Inhibitor

  • Dietary supplementImmunonutrition support

    600-1600 ml of TPF-T per day according to the nutrition status evaluation

    Also known as: enteral nutritional emulsion

06

What researchers measure

Primary outcomes

  1. 1-year Progression-free survival rate (PFS)

    Progression-free survival rate is defined the rate of progress event at 1-years after radiotherapy. Progression event is defined as event of primary tumor and regional recurrence, or distant metastasis

    Time frame: From start of treatment until 1 years of follow-up.

Secondary outcomes

  1. Objective response rate

    Response is defined by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

    Time frame: Measured at 3 months after completion of radiotherapy

  2. Progression-free survival

    Progression-free survival is defined as the time from treatment to the event of primary tumor and regional recurrence, or distant metastasis

    Time frame: Measured at months 6, 12, 18, and 24.

  3. Overall survival rate

    Live rate at months 6, 12, 18, and 24.

    Time frame: Measured at months 6, 12, 18, and 24.

  4. Overall survival

    Live status at different time points.

    Time frame: From start of treatment until 3 years of follow-up.

  5. Incidence of adverse events

    Adverse events are classified according to the Common Terminology Criteria for Adverse Events (CTCAE 5.0) criteria.

    Time frame: Measured at months 6, 12, 18, and 24.

07

Study locations

10 of 10 sites recruiting
  • Department of Radiation Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
    Beijing, Beijing Municipality 100021, China
    Recruiting
  • Department of Radiation Oncology,Clinical Oncology School of Fujian Medical University,Fujian Cancer Hospital
    Fujian, Fujian, China
    Recruiting
  • Department of Oncology, Affiliated Hospital, Hebei University of Engineering
    Handan, Hebei, China
    Recruiting
  • Department 1st of Radiation Oncology, Anyang Tumor Hospital
    Anyang, Henan, China
    Recruiting
  • Department of Radiation Oncology the first affiliated hospital of Xinxiang Medical University
    Xinxiang, Henan, China
    Recruiting
  • Department of Radiation Oncology, General Hospital of Ningxia Medical University
    Yinchuan, Ningxia, China
    Recruiting
  • Department of Radiation Oncology,Fei County People's Hospital
    Feixian, Shandong, China
    Recruiting
  • Department of Radiation Oncology, Affiliated hospital of Jining Medical University
    Jining, Shandong, China
    Recruiting
  • Tianjin Medical University Cancer Institute & Hospital
    Tianjin, Tianjin Municipality 300060, China
    Recruiting
  • Taizhou hospital of Wenzhou Medical University
    Taizhou, Zhejiang 317000, China
    Recruiting
08

References and documents

Publications

  • Park S, Oh D, Choi YL, Chi SA, Kim K, Ahn MJ, Sun JM. Durvalumab and tremelimumab with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. Cancer. 2022 Jun 1;128(11):2148-2158. doi: 10.1002/cncr.34176. Epub 2022 Mar 23. PubMed 35319779 ↗
  • Zhu Y, Wen J, Li Q, Chen B, Zhao L, Liu S, Yang Y, Wang S, Lv Y, Li J, Zhang L, Hu Y, Liu M, Xi M. Toripalimab combined with definitive chemoradiotherapy in locally advanced oesophageal squamous cell carcinoma (EC-CRT-001): a single-arm, phase 2 trial. Lancet Oncol. 2023 Apr;24(4):371-382. doi: 10.1016/S1470-2045(23)00060-8. PubMed 36990609 ↗
  • Tachihara M, Tsujino K, Ishihara T, Hayashi H, Sato Y, Kurata T, Sugawara S, Shiraishi Y, Teraoka S, Azuma K, Daga H, Yamaguchi M, Kodaira T, Satouchi M, Shimokawa M, Yamamoto N, Nakagawa K; West Japan Oncology Group (WJOG). Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Phase 2 Nonrandomized Controlled Trial. JAMA Oncol. 2023 Nov 1;9(11):1505-1513. doi: 10.1001/jamaoncol.2023.3309. PubMed 37676681 ↗
  • Ohri N, Jolly S, Cooper BT, Kabarriti R, Bodner WR, Klein J, Guha C, Viswanathan S, Shum E, Sabari JK, Cheng H, Gucalp RA, Castellucci E, Qin A, Gadgeel SM, Halmos B. Selective Personalized RadioImmunotherapy for Locally Advanced Non-Small-Cell Lung Cancer Trial (SPRINT). J Clin Oncol. 2024 Feb 10;42(5):562-570. doi: 10.1200/JCO.23.00627. Epub 2023 Nov 21. PubMed 37988638 ↗
  • Li C, Tan L, Liu X, Wang X, Zhou Z, Chen D, Feng Q, Liang J, Lv J, Wang X, Bi N, Deng L, Wang W, Zhang T, Ni W, Chang X, Han W, Gao L, Wang S, Xiao Z. Concurrent chemoradiotherapy versus radiotherapy alone for patients with locally advanced esophageal squamous cell carcinoma in the era of intensity modulated radiotherapy: a propensity score-matched analysis. Thorac Cancer. 2021 Jun;12(12):1831-1840. doi: 10.1111/1759-7714.13971. Epub 2021 May 5. PubMed 33949784 ↗
  • Liu Y, Zheng Z, Li M, Zhang Y, Zhao F, Gong H, Lin H, Huang W, Chen X, Xu Z, Li X, Liu W, Cui Y, Zheng A, Li B. Comparison of concurrent chemoradiotherapy with radiotherapy alone for locally advanced esophageal squamous cell cancer in elderly patients: A randomized, multicenter, phase II clinical trial. Int J Cancer. 2022 Aug 15;151(4):607-615. doi: 10.1002/ijc.34030. Epub 2022 Apr 27. PubMed 35419831 ↗
  • Ji Y, Du X, Zhu W, Yang Y, Ma J, Zhang L, Li J, Tao H, Xia J, Yang H, Huang J, Bao Y, Du D, Liu D, Wang X, Li C, Yang X, Zeng M, Liu Z, Zheng W, Pu J, Chen J, Hu W, Li P, Wang J, Xu Y, Zheng X, Chen J, Wang W, Tao G, Cai J, Zhao J, Zhu J, Jiang M, Yan Y, Xu G, Bu S, Song B, Xie K, Huang S, Zheng Y, Sheng L, Lai X, Chen Y, Cheng L, Hu X, Ji W, Fang M, Kong Y, Yu X, Li H, Li R, Shi L, Shen W, Zhu C, Lv J, Huang R, He H, Chen M. Efficacy of Concurrent Chemoradiotherapy With S-1 vs Radiotherapy Alone for Older Patients With Esophageal Cancer: A Multicenter Randomized Phase 3 Clinical Trial. JAMA Oncol. 2021 Oct 1;7(10):1459-1466. doi: 10.1001/jamaoncol.2021.2705. PubMed 34351356 ↗
  • Chen Y, Ye J, Zhu Z, Zhao W, Zhou J, Wu C, Tang H, Fan M, Li L, Lin Q, Xia Y, Li Y, Li J, Jia H, Lu S, Zhang Z, Zhao K. Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial. J Clin Oncol. 2019 Jul 10;37(20):1695-1703. doi: 10.1200/JCO.18.02122. Epub 2019 Mar 28. PubMed 30920880 ↗
  • You J, Zhu S, Li J, Li J, Shen J, Zhao Y, Li X, Jia L, Li Q, Yang J, Wu Y, Shen W, Wu H, Wu X, Wang X, Ren Y, He J, Lin P, Zhu G, Shi A. High-Dose Versus Standard-Dose Intensity-Modulated Radiotherapy With Concurrent Paclitaxel Plus Carboplatin for Patients With Thoracic Esophageal Squamous Cell Carcinoma: A Randomized, Multicenter, Open-Label, Phase 3 Superiority Trial. Int J Radiat Oncol Biol Phys. 2023 Apr 1;115(5):1129-1137. doi: 10.1016/j.ijrobp.2022.11.006. Epub 2022 Nov 17. PubMed 36402359 ↗
  • Yuan Y, Luo S, Wang X, Zheng Z, Qi Q, Wang Y, Chen M, Yang H, Gu P, Du Q, Wu X, Pan W, Xu Y, Wang J. Efficacy and safety of concurrent programmed cell death protein 1 inhibitor and definitive radiotherapy with immunonutrition support in esophageal squamous cell cancer: a phase II multicenter clinical trial. Radiat Oncol. 2025 Apr 18;20(1):58. doi: 10.1186/s13014-025-02604-z. PubMed 40251674 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Dec 2026, 32 months after the start.

Of 153 non-industry phase 2 interventional studies under Esophageal Squamous Cell Carcinoma, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 55. This study's planned 32 months is below that.

Counting every sponsor, half of 174 studies reached it within 41 months; a quarter within 28 and three quarters within 52.

Primary completion moved once since we started tracking on Sep 25, 2026: Jul 2026 → Dec 2026, on Oct 7, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2024
First posted
Apr 2, 2024
StartActual
Mar 14, 2024
Primary completionEst.
Dec 1, 2026was Jul 2026
CompletionEst.
Dec 1, 2026
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Recruiting
changed Oct 7, 2026
Sites
2 sites added, 1 site removed. 8 sites changed recruiting status (8 now recruiting)
Show 8 sites
  • Department of Radiation Oncology,Clinical Oncology School of Fujian Medical University,Fujian Cancer Hospital · Fujian, Chinano status→Recruiting
  • Department of Oncology, Affiliated Hospital, Hebei University of Engineering · Handan, Chinano status→Recruiting
  • Department 1st of Radiation Oncology, Anyang Tumor Hospital · Anyang, Chinano status→Recruiting
  • Department of Radiation Oncology the first affiliated hospital of Xinxiang Medical University · Xinxiang, Chinano status→Recruiting
  • Department of Radiation Oncology, General Hospital of Ningxia Medical University · Yinchuan, Chinano status→Recruiting
  • Department of Radiation Oncology,Fei County People's Hospital · Feixian, Chinano status→Recruiting
  • Department of Radiation Oncology, Affiliated hospital of Jining Medical University · Jining, Chinano status→Recruiting
  • Taizhou hospital of Wenzhou Medical University · Taizhou, Chinano status→Recruiting
Show 2 added (2 China)
  • Department of Radiation Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College · Beijing, China
  • Tianjin Medical University Cancer Institute & Hospital · Tianjin, China
Show 1 removed
  • Department of Radiation Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College · Beijing, China
Oct 7, 2026
Primary completion
Jul 1, 2026→Dec 1, 2026
Oct 7, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 40251674 ↗
Oct 7, 2026
Contact
Study contact now listed: added p•••@163.com · •••5191. See the current contact
Oct 7, 2026
Site contacts
Changed at 8 sites. See the sites
Show 8 sites
  • Department of Radiation Oncology,Clinical Oncology School of Fujian Medical University,Fujian Cancer Hospital · Fujian, ChinaContact added x•••@fjmu.edu.cn
  • Department of Oncology, Affiliated Hospital, Hebei University of Engineering · Handan, ChinaContact added q•••@163.com
  • Department 1st of Radiation Oncology, Anyang Tumor Hospital · Anyang, ChinaContact added s•••@163.comContact added (no phone or email listed)
  • Department of Radiation Oncology the first affiliated hospital of Xinxiang Medical University · Xinxiang, ChinaContact added c•••@163.com
  • Department of Radiation Oncology, General Hospital of Ningxia Medical University · Yinchuan, ChinaContact added l•••@163.com
  • Department of Radiation Oncology,Fei County People's Hospital · Feixian, ChinaContact added 5•••@qq.com
  • Department of Radiation Oncology, Affiliated hospital of Jining Medical University · Jining, ChinaContact added p•••@163.com
  • Taizhou hospital of Wenzhou Medical University · Taizhou, ChinaContact added y•••@hotmail.com
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Active, not recruiting→Recruiting
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 40251674 ↗
    2 sites added, 1 site removed. 8 sites changed recruiting status (8 now recruiting)
    Show 8 sites
    • Department of Radiation Oncology,Clinical Oncology School of Fujian Medical University,Fujian Cancer Hospital · Fujian, Chinano status→Recruiting
    • Department of Oncology, Affiliated Hospital, Hebei University of Engineering · Handan, Chinano status→Recruiting
    • Department 1st of Radiation Oncology, Anyang Tumor Hospital · Anyang, Chinano status→Recruiting
    • Department of Radiation Oncology the first affiliated hospital of Xinxiang Medical University · Xinxiang, Chinano status→Recruiting
    • Department of Radiation Oncology, General Hospital of Ningxia Medical University · Yinchuan, Chinano status→Recruiting
    • Department of Radiation Oncology,Fei County People's Hospital · Feixian, Chinano status→Recruiting
    • Department of Radiation Oncology, Affiliated hospital of Jining Medical University · Jining, Chinano status→Recruiting
    • Taizhou hospital of Wenzhou Medical University · Taizhou, Chinano status→Recruiting
    Show 2 added (2 China)
    • Department of Radiation Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College · Beijing, China
    • Tianjin Medical University Cancer Institute & Hospital · Tianjin, China
    Show 1 removed
    • Department of Radiation Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College · Beijing, China
    Primary completion Jul 1, 2026→Dec 1, 2026
    Contact Study contact now listed: added p•••@163.com · •••5191. See the current contact
    Site contacts Changed at 8 sites. See the sites
    Show 8 sites
    • Department of Radiation Oncology,Clinical Oncology School of Fujian Medical University,Fujian Cancer Hospital · Fujian, ChinaContact added x•••@fjmu.edu.cn
    • Department of Oncology, Affiliated Hospital, Hebei University of Engineering · Handan, ChinaContact added q•••@163.com
    • Department 1st of Radiation Oncology, Anyang Tumor Hospital · Anyang, ChinaContact added s•••@163.comContact added (no phone or email listed)
    • Department of Radiation Oncology the first affiliated hospital of Xinxiang Medical University · Xinxiang, ChinaContact added c•••@163.com
    • Department of Radiation Oncology, General Hospital of Ningxia Medical University · Yinchuan, ChinaContact added l•••@163.com
    • Department of Radiation Oncology,Fei County People's Hospital · Feixian, ChinaContact added 5•••@qq.com
    • Department of Radiation Oncology, Affiliated hospital of Jining Medical University · Jining, ChinaContact added p•••@163.com
    • Taizhou hospital of Wenzhou Medical University · Taizhou, ChinaContact added y•••@hotmail.com
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06342167
Responsible party
JIANYANG WANG (Principal Investigator, Cancer Institute and Hospital, Chinese Academy of Medical Sciences) — Principal investigator
First posted
Apr 2, 2024
Start date
Mar 14, 2024
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Oct 7, 2026

Study contacts

Jianyang Wang, MD
Contact
pkucell@163.com
+86-13810095191
Jianyang Wang, MD
study director · Cancer Institute and Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immune checkpoint inhibitors

Start the discussion